• Profile
Close

Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: A prospective cohort study

The Lancet Oncology Mar 10, 2019

Chae SY, et al. - In this prospective cohort study conducted in South Korea, researchers assessed whether 16α-[18F]fluoro-17β-oestradiol (18F-FES) PET-CT would be an accurate and safe diagnostic tool for the determination of oestrogen receptor status in patients with recurrent or metastatic breast cancer. Patients with breast cancer, with first recurrence or metastatic disease at presentation, having an Eastern Cooperative Oncology Group performance status of 0–2, and patients aged 19 years or older were considered eligible for inclusion in the study. They investigated whether qualitative 18F-FES PET-CT interpretation agreed to the findings of oestrogen receptor expression by immunohistochemical assay. These two modalities demonstrated high negative percent agreement. This implies that oestrogen receptor assays could be replaced with positive 18F-FES uptake by recurrent or metastatic oestrogen receptor-positive breast cancer lesions in this setting. In cases where non-feasibility of retesting oestrogen receptor status is encountered, 18F-FES PET-CT should be included in the staging evaluation.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay